

# Issues

---

- Hospital consolidation
- Shift to more expensive sites of ambulatory care
- Geographic variation in post-acute care spending
- Increases in Medicare Advantage coding intensity
- Rapid growth in Part D reinsurance payments

# Consolidation and its impact on costs

---

- There has been substantial hospital consolidation over the last two decades
- Consolidation leads to increased market power, and in turn, higher private sector prices and commercial payment rates for health care services
  - Further, there has been limited evidence of increased quality
- Hospitals have continued to obtain higher commercial rates despite slower wage growth and declines in uncompensated care

# Consolidation and its impacts on costs cont.

---

- Higher commercial rates lead to higher costs per case: MedPAC analysis finds that hospitals with less financial pressure (i.e., higher commercial reimbursements) have higher costs
- The hospitals with higher all-payer margins have very low Medicare margins

# Consolidation and its impact on hospital market competition

---

- On average, commercial payment rates are more than 50% higher than costs (some have found 75% above costs)
- Hospital all-payer profit margins reached a 30-year high in 2014, averaging 7.3 percent nationwide
- Both media and academic sources report wide payment variation for identical services within and between markets

# Consolidation and its impact on beneficiary access

---

- Higher private prices creates a disparity in payment rates and some have raised access issues
- However, we do not expect near-term access issues
  - Inpatient admissions are declining while outpatient visits are rapidly increasing
  - Occupancy rates are declining (urban 61%; rural 41%) leaving excess capacity
  - Medicare margins still sufficient to generate a 10% marginal profit on each additional Medicare patient
- Further, some hospitals currently accept discounts on Medicare rates from Medicare Select medigap plans and certain Medicare demonstrations

# Growth of hospital employment of physicians

---

- Number of physicians employed by hospitals increased by 25.5% from 2010–2014 (Bureau of Labor Statistics)
- Share of cardiologists employed by hospitals grew from 11% to 35% from 2007–2012 (ACC survey)
- Recent SK&A data shows large 1-year increases in employment

# Number of services per beneficiary growing faster in OPDs than freestanding offices, 2010–2011

Type of service	Growth in freestanding office	Growth in OPD	Share of services in OPDs, 2011
E&M office visits	-0.2%	7.8%	9.7%
Echocardiogram (without contrast)	-6.3	17.6	29.6
Nuclear cardiology	-12.0	13.6	33.0

Note: E&M (evaluation and management). Data are preliminary and subject to change

Source: MedPAC analysis of Medicare claims, 2010–2011

# If migration to OPDs continues at current rate...

---

- Medicare spending on E&M visits would be \$1.2 billion higher per year by 2021 due to shift in site of care; beneficiary cost sharing would be \$310 million higher
- Medicare spending on echocardiograms and nuclear cardiology studies would be \$1.1 billion higher per year by 2021; cost sharing would be \$285 million higher

Data are preliminary and subject to change


# Medicare Advantage coding intensity

---

- MA risk score growth higher than FFS growth
  - 8% in 2013 and 9% in 2014, cumulative
- 2017 coding intensity impact will be 10%
- CMS has applied the minimum adjustment required by law in prior 3 years
  - Minimum adjustment for 2017 is 5.66 percent

# Reinsurance has become the largest component of Part D spending


In billions of dollars



Source: MedPAC based on Table IV.B.10 of the Medicare Board of Trustees' report for 2015.

Note: Data are preliminary and subject to change.

# Growing share of Part D spending is for high-cost enrollees



- 2.9 million (7.6%) of enrollees reached OOP threshold in 2013
- Among these “high-cost enrollees,” non-LIS growing faster than LIS
- High-cost enrollees accounted for 47% of spending in 2013 (up from 40% in 2011)
- Recent growth in their spending driven by prices

# Upward pressure on prices

---

- Fewer patent expirations
- Some sharp increases in generic prices
- Drug pipeline includes many higher-priced biologics and specialty drugs
- Unprecedented launch prices, some for therapies that treat broad populations

# Use of higher-cost drugs poses challenges for Part D

---

- Share of high-cost enrollees who filled at least one prescription for a biologic product grew from 8% in 2009 to 12% in 2013\*
- Spending for new hepatitis C therapies has led to a large spike (15% increase) in Part D spending in 2014\*\*
- As more expensive therapies become available, more beneficiaries will likely reach the catastrophic phase of the benefit

\* MedPAC analysis of Part D prescription drug event data. Data are preliminary and subject to change.

\*\* Boards of Trustees, Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. 2015. *2015 annual report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Insurance Trust Funds*. Washington, DC: Boards of Trustees.